European CHMP recommends license extension of nivolumab (Opdivo) for squamous cell carcinoma

The license extension is for treatment, as monotherapy, of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.

Source:

European Medicines Agency